Histone H2A exogène induit à différenciation et la sénescence des cellules cancéreuses

Histone H2A exogène induit à différenciation et la sénescence des cellules cancéreuses

Show other versions (1)

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal

Bibliographic Details
Main Author:	Hadnagy, Annamaria
Other Authors:	Balicki, Danuta
Language:	fr
Published:	2012
Subjects:	Histone H2A Cancer du sein Sénescence Différenciation Épigénétique Inhibiteurs de l'histone déacétylase (HDACi) P21 P53 Breast cancer Senescence Differentiation Epigenetics Histone deacetylases inhibitors (HDACi)
Online Access:	http://hdl.handle.net/1866/8211

Similar Items

Histone H2A exogène induit à différenciation et la sénescence des cellules cancéreuses
by: Hadnagy, Annamaria
Published: (2012)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
by: Amit Kumar Singh, et al.
Published: (2018-06-01)

A possible link to uracil DNA glycosylase in the synergistic action of HDAC inhibitors and thymidylate synthase inhibitors
by: Meredith S. Showler, et al.
Published: (2020-10-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer
by: Dineo eKhabele
Published: (2014-05-01)

Epigenetic regulations by insulin and histone deacetylase inhibitors of the insulin signaling pathway in muscle
by: Chriett, Sabrina
Published: (2016)

Folate-mediated and pH-responsive chidamide-bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy
by: Ma Z, et al.
Published: (2019-07-01)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
by: Nikolaos Garmpis, et al.
Published: (2021-03-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01)

Expression of Adenoviral E1A in Transformed Cells as an Additional Factor of HDACi-Dependent FoxO Regulation
by: Alisa Morshneva, et al.
Published: (2019-12-01)

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
by: Mohammed I. Y. Elmallah, et al.
Published: (2019-06-01)

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
by: Patrick B. Johnston, et al.
Published: (2021-02-01)

HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines
by: Tobias S. Iveland, et al.
Published: (2020-04-01)

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
by: Chi-Yuan Chen, et al.
Published: (2020-08-01)

Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells
by: Chi-Yuan Chen, et al.
Published: (2020-02-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
by: Masumeh Sanaei, et al.
Published: (2019-01-01)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
by: Donglu Wu, et al.
Published: (2020-11-01)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
by: Lourdes Hontecillas-Prieto, et al.
Published: (2020-09-01)

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
by: Fengkun Lu, et al.
Published: (2021-01-01)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
by: Flávia Alves Verza, et al.
Published: (2020-06-01)

Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis
by: Po-Lin Liao, et al.
Published: (2019-01-01)

Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
by: Maria Mrakovcic, et al.
Published: (2019-12-01)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
by: Bin Tu, et al.
Published: (2020-06-01)

Histone Deacetylases and their Inhibitors in Cancer Epigenetics
by: Kelly N. Hassell
Published: (2019-11-01)

Up-Regulation of P21 Inhibits TRAIL-Mediated Extrinsic Apoptosis, Contributing Resistance to SAHA in Acute Myeloid Leukemia Cells
by: Xing Wu, et al.
Published: (2014-08-01)

CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma
by: Roberta Antonelli, et al.
Published: (2020-07-01)

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
by: Afaloniati H, et al.
Published: (2020-06-01)

Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells
by: Yueh-Ming Shyu, et al.
Published: (2021-09-01)

A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation
by: Umasankar De, et al.
Published: (2018-09-01)

The Role of HDACs as Leukemia Therapy Targets using HDI
by: Ahmad Ahmadzadeh, et al.
Published: (2016-02-01)

Expression of Class I Histone Deacetylases in Insect Cells
by: Bryan, Erin E
Published: (2006)

Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2–p53 signaling
by: Xie C, et al.
Published: (2016-07-01)

Histone acetylation modifiers in the pathogenesis of Alzheimer’s disease
by: Xi eLu, et al.
Published: (2015-06-01)

ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1
by: Ferdinando Maria Milazzo, et al.
Published: (2020-01-01)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
by: Robert Jenke, et al.
Published: (2021-02-01)

Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents
by: Subhasish Tapadar, et al.
Published: (2020-10-01)

The Role of Post-Translational Acetylation and Deacetylation of Signaling Proteins and Transcription Factors after Cerebral Ischemia: Facts and Hypotheses
by: Svetlana Demyanenko, et al.
Published: (2021-07-01)

Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain
by: Pritika J. Narayan, et al.
Published: (2015-02-01)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
by: Shalome A. Bassett, et al.
Published: (2014-10-01)

Subcellular localization of class I histone deacetylases in the developing Xenopus tectum
by: Xia eGuo, et al.
Published: (2016-01-01)

Cannot write session to /tmp/vufind_sessions/sess_16ipirhdd4gbh8psjseqvt2m15